有症状COVID-19患者的肺炎频率与严重程度:mRNA疫苗与腺病毒载体疫苗的影响
这项回顾性单中心研究纳入467例有症状COVID-19住院患者,比较未接种与全程接种BNT162b2 mRNA疫苗或ChAdOx1-S腺病毒载体疫苗者胸部CT肺炎频率和严重程度。全程接种者无肺炎比例更高、CT严重程度评分更低、双侧受累更少,提示疫苗对突破感染者的肺损伤有保护作用。
要点
- 未接种者无肺炎比例15%,ChAdOx1-S全程接种者29%,BNT162b2全程接种者51%。
- 未接种者平均CT-SS为9.7±6.1,高于BNT162b2的5.2±6.1和ChAdOx1-S的6.2±5.9。
- 未接种者双侧受累86%,ChAdOx1-S接种者90%,均高于BNT162b2接种者的57%。
核心结论
- 全程接种mRNA或腺病毒载体疫苗的突破感染者,肺炎频率和严重程度均低于未接种者。
研究设计与样本
- 回顾性单中心研究,纳入467例有症状COVID-19住院患者(男250例、女217例,平均年龄65±17岁),均经逆转录聚合酶链反应确诊并接受胸部CT检查。
关键影像表现/征象
- 未接种者无肺炎比例为15%(32/216),ChAdOx1-S全程接种者为29%(24/84),BNT162b2全程接种者为51%(85/167)。
- 未接种者平均CT-SS为9.7±6.1,BNT162b2全程接种者为5.2±6.1,ChAdOx1-S全程接种者为6.2±5.9。
- 未接种者双侧肺受累比例为86%(158/184),ChAdOx1-S全程接种者为90%(54/60),BNT162b2全程接种者为57%(47/82)。
诊断标准与关键数值
- CT-SS采用0-25分半定量评分,0分表示无肺炎。
- 全程接种定义为COVID-19诊断前至少14天已接种第二剂疫苗。
- 未接种与ChAdOx1-S全程接种者无肺炎比例差异p=.08,未达统计学显著。
- 未接种与ChAdOx1-S全程接种者无肺炎比例均与BNT162b2全程接种者比较,p<.001。
- 全程接种与CT-SS显著相关且独立于年龄和性别(估计值=-4.46,p<.001)。
临床应用与阅片要点
- 对有症状COVID-19住院患者行胸部CT时,可结合疫苗接种类型解读肺炎频率和CT-SS。
- 突破感染者仍可出现肺炎,未接种者肺炎频率更高、CT-SS更高、双侧受累更常见。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND. Additional evidence of the role of COVID-19 vaccination in reducing pneumonia frequency and severity in the setting of breakthrough infection could help combat ongoing vaccine hesitancy. OBJECTIVE. The purpose of this article was to compare the frequency and severity of pneumonia on chest CT in patients with confirmed COVID-19 between patients who are unvaccinated and those who are fully vaccinated by messenger RNA (mRNA) or adenovirus vector vaccines. METHODS. This retrospective single-center study included 467 patients (250 men, 217 women; mean age, 65 ± 17 [SD] years) who underwent chest CT between December 15, 2021, and February 18, 2022, during hospitalization for symptomatic COVID-19, confirmed by reverse transcriptase-polymerase chain reaction assay. A total of 216 patients were unvaccinated, and 167 and 84 patients were fully vaccinated (defined as receipt of the second dose at least 14 days before COVID-19 diagnosis) by the BNT162b2 mRNA vaccine or the ChAdOx1-S adenovirus vector vaccine, respectively. Semiquantitative CT severity scores (CT-SS; 0-25 scale) were determined; CT-SS of 0 indicated absence of pneumonia. Presence of bilateral involvement was assessed in patients with pneumonia. Associations were explored between vaccination status and CT findings. RESULTS. The frequency of the absence of pneumonia was 15% (32/216) in unvaccinated patients, 29% (24/84) in patients fully vaccinated with ChAdOx1-S vaccine, and 51% (85/167) in patients fully vaccinated with BNT162b2 vaccine (unvaccinated and ChAdOx1-S vs BNT162b2: p < .001; unvaccinated vs ChAdOx1-S: p = .08). Mean CT-SS was significantly higher in unvaccinated patients (9.7 ± 6.1) than in patients fully vaccinated with BNT162b2 (5.2 ± 6.1) or ChAdOx1-S (6.2 ± 5.9) vaccine (both p < .001). Full vaccination was significantly associated with CT-SS independent of patient age and sex (estimate = -4.46; p < .001). Frequency of bilateral lung involvement was significantly higher in unvaccinated patients (158/184, 86%) and in patients fully vaccinated with ChAdOx1-S vaccine (54/60, 90%) than in patients fully vaccinated with BNT162b2 vaccine (47/82, 57%) (both p < .001). CONCLUSION. Pneumonia frequency and severity were lower in patients with full vaccination by mRNA and adenovirus vector vaccines who experienced breakthrough infections in comparison with unvaccinated patients. CLINICAL IMPACT. The visual observation by radiologic imaging of the protective effect of vaccination on lung injury in patients with breakthrough infections provides additional evidence supporting the clinical benefit of vaccination.
引用
- Vicini, Bellini, Iannarelli, et al. Pneumonia Frequency and Severity in Patients With Symptomatic COVID-19: Impact of mRNA and Adenovirus Vector Vaccines. AJR Am J Roentgenol. 2022. PMID: 35642761. doi:10.2214/AJR.22.27843
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。